• # LGM Pharma is a Efalizumab CAS# 214745-43-4 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Efalizumab
  • CAS #: 214745-43-4
  • Mode of Action:

    Efalizumab binds to CD11a, a subunit of leukocyte function antigen-1 (LFA-1), which is expressed on all leukocytes. As a result efalizumab decreases cell surface expression of CD11a.

  • Pharmacodynamics:

    Lymphocyte activation and trafficking to skin play a role in the pathophysiology of chronic plaque psoriasis. In psoriatic skin, ICAM-1 cell surface expression is upregulated on endothelium and keratinocytes. Raptiva inhibits the binding of LFA-1 to the intercellular adhesion molecule-1 (ICAM-1), thereby inhibiting the adhesion of leukocytes to other cell types.

  • IUPAC: Immunoglobulin G1, anti-(human CD11a (antigen)) (human-mouse monoclonal hu1124 gamma1-chain), disulfide with human-mouse monoclonal hu1124 light chain, dimer
  • ATC: L04AA21
  • DrugBank: DB00095
  • Synonyms: anti-CD11a, Efalizumab, HSDB 7847, Hu 1124, hu1124, Immunoglobulin G 1 (human-mouse monoclonal hu1124 gamma1-chain anti-human antigen CD 11a), disulfide with human-mouse monoclonal hu1124 light chain, dimer. Molecular weight is approximately 146,170 daltons, Raptiva, UNII-XX2MN88N5D, Xanelim
  • AHFS Code: 84:92.00
  • General Reference:


    1. Pubmed
    2. Descamps V: [Efalizumab] Ann Dermatol Venereol. 2006 Aug-Sep;133(8-9 Pt 1):666-78. Pubmed


Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants


  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service